

ORIGINAL ARTICLE

## BCR–ABL-mediated upregulation of *PRAME* is responsible for knocking down *TRAIL* in CML patients

DD De Carvalho<sup>1,2</sup>, R Binato<sup>3,9</sup>, WO Pereira<sup>1,2,9</sup>, JMG Leroy<sup>1,2</sup>, MD Colassanti<sup>4</sup>, R Proto-Siqueira<sup>5</sup>, AEB Bueno-Da-Silva<sup>1,2</sup>, MA Zago<sup>6</sup>, MA Zanichelli<sup>4</sup>, E Abdelhay<sup>3</sup>, FA Castro<sup>2,7</sup>, JF Jacysyn<sup>8</sup> and GP Amarante-Mendes<sup>1,2</sup>

<sup>1</sup>Departamento de Imunologia, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, Brazil; <sup>2</sup>Instituto de Investigação em Imunologia, Instituto Nacional de Ciência e Tecnologia, São Paulo, Brazil; <sup>3</sup>Divisão de Laboratórios do CEMO, Instituto Nacional de Câncer, Rio de Janeiro, Brazil; <sup>4</sup>Hospital Brigadeiro, São Paulo, Brazil; <sup>5</sup>Fleury Medicine and Health, São Paulo, Brazil; <sup>6</sup>Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, São Paulo, Brazil; <sup>7</sup>Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, São Paulo, Brazil and <sup>8</sup>Faculdade de Medicina—LIM62, Universidade de São Paulo, São Paulo, Brazil

Tumor necrosis factor-related apoptosis-inducing ligand—TNFSF10 (*TRAIL*), a member of the TNF- $\alpha$  family and a death receptor ligand, was shown to selectively kill tumor cells. Not surprisingly, *TRAIL* is downregulated in a variety of tumor cells, including BCR–ABL-positive leukemia. Although we know much about the molecular basis of *TRAIL*-mediated cell killing, the mechanism responsible for *TRAIL* inhibition in tumors remains elusive because (a) *TRAIL* can be regulated by retinoic acid (RA); (b) the tumor antigen preferentially expressed antigen of melanoma (*PRAME*) was shown to inhibit transcription of RA receptor target genes through the polycomb protein, enhancer of zeste homolog 2 (*EZH2*); and (c) we have found that *TRAIL* is inversely correlated with *BCR–ABL* in chronic myeloid leukemia (CML) patients. Thus, we decided to investigate the association of *PRAME*, *EZH2* and *TRAIL* in BCR–ABL-positive leukemia. Here, we demonstrate that *PRAME*, but not *EZH2*, is upregulated in BCR–ABL cells and is associated with the progression of disease in CML patients. There is a positive correlation between *PRAME* and *BCR–ABL* and an inverse correlation between *PRAME* and *TRAIL* in these patients. Importantly, knocking down *PRAME* or *EZH2* by RNA interference in a BCR–ABL-positive cell line restores *TRAIL* expression. Moreover, there is an enrichment of *EZH2* binding on the promoter region of *TRAIL* in a CML cell line. This binding is lost after *PRAME* knockdown. Finally, knocking down *PRAME* or *EZH2*, and consequently induction of *TRAIL* expression, enhances Imatinib sensibility. Taken together, our data reveal a novel regulatory mechanism responsible for lowering *TRAIL* expression and provide the basis of alternative targets for combined therapeutic strategies for CML.

*Oncogene* (2011) 30, 223–233; doi:10.1038/onc.2010.409; published online 13 September 2010

**Keywords:** *PRAME*; *TRAIL*; TNFSF10; *EZH2*; CML; BCR–ABL

### Introduction

Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder of transformed hematopoietic progenitor cells. It is characterized by the Philadelphia chromosome, which is generated by a t(9;22)(q34;q11) translocation (Kurzrock *et al.*, 1988; Sawyers, 1999). This translocation results in the appearance of the constitutively active chimeric protein tyrosine kinase BCR–ABL, a hallmark of CML (Sawyers, 1997). Expression of BCR–ABL activates multiple signaling pathways leading to proliferation, reduced growth factor dependence, abnormal interaction with the bone marrow extracellular matrix and to a state of extreme resistance to apoptosis (Bedi *et al.*, 1994; Amarante-Mendes *et al.*, 1997, 1998; McGahon *et al.*, 1997; Brumatti *et al.*, 2003). Although the development of tyrosine-kinase inhibitors has revolutionized the treatment of BCR–ABL-positive leukemia, it has become increasingly clear that treatment with tyrosine-kinase inhibitors alone will not be curative in many cases, in particular in the advanced phase of the disease (Melo and Barnes, 2007). Thus, proper knowledge of molecular alterations triggered by the expression of BCR–ABL, especially during the disease progression, should provide rationale for the development of novel therapeutic strategies for CML.

Tumor necrosis factor-related apoptosis-inducing ligand—TNFSF10 (*TRAIL*) is a type II transmembrane protein belonging to the TNF- $\alpha$  family that is constitutively expressed in a wide range of tissues (Wiley *et al.*, 1995). *TRAIL* is critically involved in anti-cancer surveillance by immune cells (Takeda *et al.*, 2001, 2002, 2004; Schmaltz *et al.*, 2002) and also has the ability to trigger apoptosis in a cell autonomous way, in a variety of tumor cell lines, but

Correspondence: Dr GP Amarante-Mendes, Departamento de Imunologia, Instituto de Ciências Biomédicas—Universidade de São Paulo, Av Professor Lineu Prestes, 1730—Cidade Universitária, São Paulo, SP 05508-900, Brazil.

E-mail: gpam@usp.br

<sup>9</sup>These authors contributed equally to the work.

Received 15 March 2010; revised 11 July 2010; accepted 29 July 2010; published online 13 September 2010

not in most normal cells (Walczak *et al.*, 1999; Wang and El-Deiry, 2003). Importantly, TRAIL<sup>-/-</sup> mice display an increased susceptibility to tumor initiation and metastasis (Cretney *et al.*, 2002; Sedger *et al.*, 2002), highlighting the importance of TRAIL in the defense against tumors. Therefore, it is not surprising that one of the key mechanisms of tumor escape is a general downregulation of TRAIL. Despite the enormous amount of knowledge gained in the last few years on TRAIL regulation and TRAIL-mediated cell death, the molecular basis of TRAIL inhibition in tumors is poorly understood.

Preferentially expressed antigen of melanoma (PRAME) is over-expressed in a variety of neoplasia, such as melanoma, breast carcinomas, renal cell carcinomas, non-small cell lung carcinomas, head and neck cancers, Hodgkin's lymphomas, medulloblastomas, sarcomas, Wilm's tumors, myelocytic and lymphocytic leukemia (Epping and Bernards, 2006), but its expression is low or absent in normal tissues (Ikeda *et al.*, 1997). Although PRAME can trigger autologous cytotoxic T cell-mediated immune responses, its expression is preserved in several tumor cells, suggesting that PRAME expression can confer a selective advantage that outweighs its role in CTL-mediated tumor killing (Ikeda *et al.*, 1997; Epping and Bernards, 2006). The manner in which PRAME over-expression contributes to the tumorigenic process still remains elusive.

We have recently observed that TRAIL is down-regulated by BCR-ABL in cell lines as well as in peripheral blood mononuclear cells obtained from CML patients (JMGL and GPA-M, unpublished observations). Importantly, we found that decreased levels of TRAIL were associated with the progression of the disease. As it is known that TRAIL can respond to retinoic acid (RA) (Walczak *et al.*, 1999; Altucci *et al.*, 2001; Clarke *et al.*, 2004) and that PRAME can act as a dominant repressor of RA/RA receptor signaling (Epping *et al.*, 2005), we decided to investigate a possible association between upregulation of PRAME and decreased levels of TRAIL in CML.

We report here that BCR-ABL-mediated upregulation of PRAME is the molecular event responsible for knocking down TRAIL in Philadelphia chromosome-positive leukemia. The expression of polycomb protein enhancer of zeste homolog 2 (EZH2), which is necessary for PRAME-mediated transcriptional inhibition of TRAIL, is not altered in the presence of BCR-ABL. Finally, *in silico* analysis of gene-expression profiling studies suggest that the downregulation of TRAIL by PRAME may be a more general phenomenon characteristic of a variety of tumors. This implicates the transcription-repressive activity of the PRAME/EZH2 complex in the TRAIL promoter as a possible major target for novel anti-cancer therapies.

## Results

### PRAME but not EZH2 is a BCR-ABL-induced gene

We first surveyed human leukemia cell lines for expression of PRAME and EZH2 and verified that cell


lines endogenously expressing BCR-ABL, such as KBM7, LAMA8.4 and K562, showed higher expression of PRAME than the BCR-ABL-negative cell lines, SKW6.4, THP1 and HL60 (Figure 1a). This result was confirmed by western blot (Supplementary Figure 1). The expression of EZH2 was not significantly different between BCR-ABL-positive and -negative cells (Figure 1b). To confirm that the relatively higher level of PRAME is a direct consequence of the expression of BCR-ABL, we compared the mRNA levels of PRAME in our HL-60.vector and HL-60.Bcr-Abl cell line and verified that the ectopic expression of BCR-ABL dramatically upregulated PRAME (Figure 1c). Interestingly, the treatment of BCR-ABL-positive cells, K562 and HL60.BCR-ABL, with 10  $\mu$ M of Imatinib for 8 or 24 h does not decrease PRAME expression (Supplementary Figure 2). This result suggests that although PRAME expression can be induced in the presence of BCR-ABL, its tyrosine kinase activity is not necessary to maintain high PRAME expression.

Next, we quantitatively determined the mRNA of PRAME and EZH2 in peripheral blood mononuclear cells from healthy individuals and CML patients in different phases of the disease. We found that PRAME (Figure 1d), but not EZH2 (Figure 1e), was upregulated in CML patients when compared with the healthy controls. In addition, there was significant positive correlation between levels of PRAME and BCR-ABL (Figure 1f;  $P < 0.0001$ ,  $r_s = 0.6117$ ). Altogether, these data confirm that PRAME, but not EZH2, is positively regulated by BCR-ABL and that PRAME expression correlates with the progression of CML in our cohort of patients.

### PRAME is responsible for BCR-ABL-mediated repression of TRAIL

In light that PRAME acts as a dominant repressor of RA/RA receptor signaling (Epping *et al.*, 2005) and that TRAIL can be induced by RA treatment (Altucci *et al.*, 2001; Clarke *et al.*, 2004), we established a relationship analysis between the absolute gene expression of PRAME and TRAIL in our cohort of CML patients. We found out a moderate but significant inverse correlation ( $P = 0.0009$ ,  $r_s = -0.4971$ ) between the expression of these two genes (Figure 2a). In comparison, we found no correlation between EZH2 and TRAIL (Figure 2b). It is important to note that the patients with higher TRAIL expression were in the chronic phase, while the patients with lower expression were in the advanced phases of the disease. This strengthens the hypothesis that decreased TRAIL expression may be important in the pathogenesis of CML.

To further confirm that the downregulation of TRAIL detected in BCR-ABL-positive cells is a direct consequence of BCR-ABL-mediated upregulation of PRAME, we generated a CML blastic crisis-derived cell line, namely K562, stably infected with short hairpin RNA against PRAME (K562.PRAME<sup>KD</sup>). We specifically chose this cell line because of its high resistance to TRAIL-mediated cell death (Nimmanapalli *et al.*, 2001). The sequence-specific short hairpin RNA vector




**Figure 1** *PRAME*, but not *EZH2*, is a BCR-ABL-induced gene and is upregulated during the disease progression. (a) RT-qPCR analysis of *PRAME* mRNA in different leukemia cell lines. The BCR-ABL<sup>+</sup> cells show higher *PRAME* expression than the BCR-ABL<sup>-</sup> cells. (b) RT-qPCR analysis of *EZH2* mRNA in different leukemia cell lines. There is no difference in *EZH2* expression between the BCR-ABL-positive and -negative cells. (c) RT-qPCR analysis of *PRAME* expression in HL-60 empty vector (HL60) and HL60.BCR-ABL, which ectopically expresses BCR-ABL, cell lines. The graph shows a dramatic upregulation of *PRAME* after the BCR-ABL transfection. (d) Relative expression of *PRAME* in healthy individuals (control) and CML patients in chronic (CP), accelerated (AP), blastic phase (BP), and in patients who achieved complete cytogenetic remission (CCyR). The lines represent the median values. (e) Relative expression of *EZH2* in healthy individuals (control) and CML patients in chronic (CP), accelerated (AP), blastic phase (BP), and in patients who achieved complete cytogenetic remission (CCyR). (f) Correlation between *PRAME* and BCR-ABL in all CML patients. Spearman's  $R = 0.6117$ ,  $P < 0.0001$ . \*\* $P < 0.01$ .

pRS-PRAME significantly reduced endogenous *PRAME* mRNA (Figure 2c) and protein (Figure 2d) in K562 cells. As expected, knocking down *PRAME* significantly increased the levels of *TRAIL* found in wild-type K562 cells (Figure 2e). This result is in agreement with a direct role of PRAME as a repressor of *TRAIL* in BCR-ABL-positive leukemia cell lines.

#### *EZH2* is required for PRAME-mediated repression of TRAIL

Despite the fact that the expression of *EZH2* is not modulated by BCR-ABL, *EZH2* was shown to be required for the transcriptional repression activity of

*PRAME* (Epping *et al.*, 2005). Therefore, we tested the functional relevance of *EZH2* in PRAME-mediated repression of *TRAIL*. We inhibited endogenous *EZH2* in K562 cells using two specific short hairpin RNA vectors (Figures 3a and b) and obtained K562.EZH2<sup>KD</sup> cells. As a result of *EZH2* downregulation, *TRAIL* expression increased significantly (Figure 3c). Importantly, *EZH2* knockdown does not lead to PRAME destabilization, nor does PRAME knockdown lead to *EZH2* destabilization (Supplementary Figure 3). These data argue that although expression of *EZH2* does not seem to be changed in the presence of BCR-ABL, it is still an important mediator of PRAME-dependent repression of *TRAIL*.



**Figure 2** PRAME is responsible for knocking down *TRAIL* expression in CML. Correlation between *PRAME* and *TRAIL* (a) and *EZH2* and *TRAIL* (b) absolute expression in all CML patients shown in Figure 1d. RT-qPCR (c) and western blot (d) analysis of *PRAME* expression in K562 wild type (WT) or stably transfected with pRS (empty vector), or with two infections with pRS-*PRAME* to knock down endogenous *PRAME* (indicated as *PRAME*<sup>KD</sup>). (e) RT-qPCR analysis of *TRAIL* mRNA in K562 cell lines before and after *PRAME* knockdown. \**P* < 0.05; \*\**P* < 0.01.

In order to gain a better understanding of the role of *EZH2* in *PRAME*-mediated repression of *TRAIL*, we performed chromatin immunoprecipitation assay using an antibody against *EZH2*. We found that in the K562 cell line wherein *PRAME* is highly expressed, *EZH2* is enriched at the *TRAIL* promoter (Figure 4b). We hypothesized that aberrant binding of *EZH2* to the *TRAIL* promoter is dependent on *PRAME* activity. To test this, we compared by chromatin immunoprecipitation assay the binding of *EZH2* to *TRAIL* promoter in the presence and absence of *PRAME*. As expected, there is a significant loss of *EZH2* from the *TRAIL* promoter in K562.*PRAME*<sup>KD</sup> cells (Figure 4b). Taken together, our data clearly show that the high levels of *PRAME*, mediated by BCR-ABL signaling, is responsible for the aberrant targeting of the endogenous *EZH2* to the *TRAIL* promoter and, consequently, silencing of this tumor suppressor gene.


#### *PRAME* or *EZH2* knocking down enhances Imatinib sensitivity in a CML cell line

We next sought to investigate whether this novel regulatory mechanism could be used as a secondary target for CML treatment. We treated K562.vector, K562.*PRAME*<sup>KD</sup> or K562.*EZH2*<sup>KD</sup> with increasing doses of Imatinib and measured cell death after 48 h by propidium iodide incorporation into the DNA and cell viability by Trypan blue exclusion. We found a statistically significant increase in apoptosis and a concomitant decrease in cell viability in K562.*PRAME*<sup>KD</sup> and K562.*EZH2*<sup>KD</sup> cells treated with Imatinib


when compared with the empty vector control (Figures 5a and b). To confirm that *TRAIL*, instead of other putative *PRAME* targets, is responsible for the enhanced susceptibility of K562.*PRAME*<sup>KD</sup> and K562.*EZH2*<sup>KD</sup> cells to Imatinib, we treated every cell line with Imatinib for 72 h in the presence or absence of *TRAIL* R2-Fc (a protein able to inhibit *TRAIL*-induced apoptosis). The increased apoptosis observed in Imatinib-treated K562.*PRAME*<sup>KD</sup> and K562.*EZH2*<sup>KD</sup> was not seen when cells were treated in the presence of *TRAIL* R2-Fc (Figure 5c). Our results suggest that therapeutic strategies targeting *PRAME* and/or *EZH2*, and consequently restoring *TRAIL* expression, can be an interesting avenue for increasing Imatinib efficiency in CML.

#### *TRAIL* re-expression after *PRAME* or *EZH2* knockdown can kill *TRAIL*-sensitive cells

In order to investigate whether the re-expression of *TRAIL* in K562.*PRAME*<sup>KD</sup> or K562.*EZH2*<sup>KD</sup> (Figures 2e and 3c) is functionally active, we co-cultured the K562 cell lines with the *TRAIL*-sensitive, carboxy-fluorescein diacetate succinimidyl ester-labeled Jurkat cells, in the ratio of 3:1. First, we showed that Jurkat cells are indeed *TRAIL*-sensitive, by treating the cells with different concentrations of isoleucine-zipper-*TRAIL*, a version of recombinant *TRAIL*. As shown in Figure 6a, apoptosis can be significantly induced in Jurkat cells with doses as low as 40 ng/ml of isoleucine-zipper-*TRAIL*. Second, we found that Jurkat cells underwent significantly more apoptosis when co-cultured



**Figure 3** EZH2 knockdown restores TRAIL expression. RT-qPCR (a) and western blot (b) analysis of *EZH2* expression in K562 wild type (WT) or stably transfected with pRS (empty vector) or pRS-EZH2 #3 (shRNA 1) or pRS-EZH2 #4 (shRNA 2), or with two different shRNAs to knock down endogenous *EZH2* (indicated as *EZH2*<sup>KD</sup>). (c) RT-qPCR analysis of *TRAIL* mRNA in K562 cell lines before and after *EZH2* knockdown. \**P*<0.05; \*\**P*<0.01.



**Figure 4** PRAME-mediated EZH2 binding to TRAIL promoter. (a) Schematic representation of the TRAIL promoter using the Gene2Promoter software from Genomatix (<http://www.genomatix.de>). (b) ChIP analysis of EZH2 binding to TRAIL promoter in K562 wild type (WT) and K562, wherein endogenous PRAME cells were knocked down (indicated as PRAME<sup>KD</sup>). Bound and unbound fractions were quantified and used to calculate bound/input ratio. \*\**P*<0.01. RARE, retinoic acid responsive element; TSS, transcript start site.


with K562.PRAME<sup>KD</sup> or K562.EZH2<sup>KD</sup> cells compared with K562.vector cells (Figure 6b).

*Inverse correlation between PRAME and TRAIL in different tumors*

Finally, we addressed whether the downregulation of TRAIL by PRAME is a general phenomenon in cancer patients. We performed a meta-analysis using the Oncomine platform (<http://www.oncomine.org>). By assessing six studies and more than 200 samples of lung adenocarcinoma, melanoma, breast carcinoma and matched healthy tissues (Figure 7), we could find several situations wherein the expression of PRAME was inversely correlated with the expression of TRAIL, suggesting that TRAIL could indeed be a target for transcriptional regulation by PRAME in a variety of cancer.

**Discussion**

Increasing evidences show that TRAIL can act as a tumor suppressor. First, TRAIL knockout mice are more susceptible to tumorigenesis induced by chemical carcinogens and metastasis (Cretney *et al.*, 2002; Sedger *et al.*, 2002). Second, experiments that used neutralizing antibodies against TRAIL demonstrated that it could significantly increase liver metastases in mice (Cretney *et al.*, 2002; Clarke *et al.*, 2004). Indeed, several expression-profiling surveys in cancer have shown that TRAIL expression is lost upon cancer progression (Daniels *et al.*, 2005; Popnikolov *et al.*, 2006; Vigneswaran *et al.*, 2007) and there are diverse studies demonstrating that TRAIL expression is a central mediator of apoptosis in some cancer treatments such as RA, histone deacetylase inhibitors and interferon (Altucci *et al.*, 2001; Clarke *et al.*, 2004; Insinga *et al.*,




**Figure 5** PRAME<sup>KD</sup> and EZH2<sup>KD</sup> enhance Imatinib-mediated cell death in K562 cell line in a TRAIL-dependent way. (a) Cell cycle analysis after 48-h treatment with indicated doses of Imatinib. Apoptosis was estimated by measuring the number of cells with subdiploid DNA content. The figure shows representative data of three independent experiments. (b) Graphical representation of the three experiments in a (left panel). Cell viability was measured by Trypan Blue exclusion (right panel). (c) Percentage of Annexin V-positive cells after treatment with TRAIL R2-Fc, STI571 or both for 72 h. Annexin V staining shows the percentage of apoptotic cells. \* $P < 0.05$ ; \*\*\* $P < 0.001$ .

2005; Nebbioso *et al.*, 2005). These data suggest that *TRAIL* downregulation has a central role in tumor initiation and/or progression, and that *TRAIL* re-expression is a promising therapeutic avenue for killing transformed cell lines without affecting normal cells.

*PRAME* is frequently expressed in many different cancers (Epping and Bernards, 2006), including BCR-ABL-positive leukemia (Watari *et al.*, 2000; Radich *et al.*, 2006; Yong *et al.*, 2008). We confirmed that *PRAME* is a target for BCR-ABL tyrosine-kinase signaling pathways and showed that *PRAME* expression correlates well with *BCR-ABL* in CML patients, in particular, as a marker of disease progression. Furthermore, our results substantiate the suggestion that *PRAME* over-expression is involved in tumorigenesis,

possibly by suppressing the RA signaling pathway (Epping *et al.*, 2005). *PRAME* can bind to the RA receptor in the presence of RA and prevent receptor activation and target gene transcription. This mechanism seems to require the histone methyltransferase activity of the polycomb protein, EZH2, which forms a complex with *PRAME* and mediates the epigenetic silencing of the RA target genes (Epping *et al.*, 2005). As a result, *PRAME* may be able to confer growth or survival advantages to cancer cells. However, this mechanism has been well established only in melanoma and, presently, it is not clear whether *PRAME* inhibits RA signaling in other forms of cancer. In fact, *PRAME* expression was not found to be associated with the downregulation of RA signaling in acute myeloid



**Figure 6** K562.PRAME<sup>KD</sup> or K562.EZH2<sup>KD</sup> can kill TRAIL-sensitive cells. (a) Jurkat cells are sensitive to isoleucine-zipper-TRAIL, a recombinant version of TRAIL. (b) K562.PRAME<sup>KD</sup> or K562.EZH2<sup>KD</sup> can induce significantly more apoptosis in TRAIL-sensitive JURKAT cells than K562 empty vector. \* $P < 0.05$ ; \*\* $P < 0.01$ ; \*\*\* $P < 0.001$ .

leukemia (Steinbach *et al.*, 2007). Interestingly, although PRAME is an independent prognostic marker of poor clinical outcome in different solid tumors (van't Veer *et al.*, 2002; Oberthuer *et al.*, 2004), in childhood acute myeloid leukemia patients, PRAME was rather suggested to be a marker of favorable prognosis (Tajeddine *et al.*, 2008).

Another important point that remains obscure is the nature of the target genes that are repressed by the PRAME–EZH2 complex and are vital for more than one aspect of tumorigenesis. At the moment, only the *p21* and *RAR $\beta$*  expression levels were shown to be downregulated in melanoma cells in a PRAME-dependent manner (Epping *et al.*, 2005). We hypothesize that TRAIL expression could be regulated by PRAME. First, PRAME is a dominant repressor of RA receptor signaling (Epping *et al.*, 2005), whereas TRAIL is a gene inducible by RA treatment. Second, PRAME is capable of inhibiting the induction of apoptosis by histone

deacetylase inhibitors in a concentration-dependent manner (Epping *et al.*, 2007), an event shown to be modulated, at least in leukemia, by induction of TRAIL expression (Insinga *et al.*, 2005; Nebbioso *et al.*, 2005). Indeed, our results clearly showed that in the CML line K562, the inhibition of TRAIL expression is mediated by PRAME and this process relies on EZH2 binding to the TRAIL promoter. We specifically chose this cell line because of its relative resistance to TRAIL-mediated cell death, allowing cells to survive after TRAIL re-expression. In comparison, we were not able to select viable cells when we tried to stably knock down PRAME or EZH2 in TRAIL-sensitive cell lines (data not shown). We are currently verifying whether this effect is indeed mediated by upregulation of TRAIL in these cells.

It is known that TRAIL frequently induces apoptosis in BCR–ABL-positive leukemia cells (Uno *et al.*, 2003) and it was suggested that TRAIL production can overcome Imatinib mesylate resistance in CML cell lines (Kikuchi *et al.*, 2007). This information is in agreement with our data showing that K562 cells with an artificial reduction in PRAME or EZH2 expression are more sensitive to Imatinib treatment owing to increased TRAIL expression. As the anti-apoptotic protein c-FLIP is known to participate in the regulation of Imatinib-induced cell death (Nimmanapalli *et al.*, 2001), we assessed whether knocking down PRAME or EZH2 could lead to destabilization of c-FLIP. We did not observe downregulation of c-FLIP in K562.PRAME<sup>KD</sup> and K562.EZH2<sup>KD</sup> cells (Supplementary Figure 3), suggesting that TRAIL is indeed the major PRAME target responsible for enhanced susceptibility to Imatinib.


Taken together, our results open new therapeutic possibilities for combined treatment of CML patients. In fact, co-treatment with Imatinib mesylate enhances TRAIL-induced apoptosis of BCR–ABL-positive cell lines, even in K562, a TRAIL-resistant cell line (Nimmanapalli *et al.*, 2001). Therefore, interference in the expression of PRAME or in the activity of histone methyltransferase of EZH2 may be a good alternative or co-adjuvant strategy for CML.

Finally, by analyzing the expression changes in cancer microarray databases, using the OncoPrint platform, we found that several forms of cancer, such as lung adenocarcinomas, melanomas and breast carcinomas, show a higher PRAME expression associated with a lower TRAIL expression when compared with matched healthy tissues. These data correlate with our *in vitro* knockdown results suggesting that PRAME may be involved in the tumorigenic process in a wide range of cancers, at least in part by blocking the tumor suppressor pathway mediated by TRAIL expression.

## Materials and methods

### Patient samples

All samples were collected, under the protocols approved by all Hospitals and Institutional Ethics Committees, after obtaining patients' written informed consent. Peripheral blood was collected from 10 healthy individuals and 40 CML



**Figure 7** TRAIL is downmodulated in lung adenocarcinoma, melanoma and breast carcinoma, while PRAME is upregulated. Box plots showing decreased expression of TRAIL and increased expression of PRAME on datasets performed in lung adenocarcinoma (Beer *et al.*, 2002; Stearman *et al.*, 2005) (a); melanoma (Haqq *et al.*, 2005; Hoek *et al.*, 2006) (b); and breast carcinoma (Richardson *et al.*, 2006) (c). The y-axis represents normalized expression. Shaded boxes represent the interquartile range (25th–75th percentile). Whiskers represent the 10th–90th percentile. The bars denote the median.

patients (11 chronic phase, 10 accelerated phase, 10 blastic phase and 9 with complete cytogenetic remission (CCyR) post-Imatinib mesylate (Gleevec, Novartis, Basel, Switzerland) (400 mg/day)). CML diagnosis of the patients enrolled in this study was confirmed by Philadelphia chromosome and *BCR-ABL* rearrangement detection. Peripheral blood mononuclear cells from patients and controls were isolated according to standard protocol with the Ficoll-Hypaque 1077 density technique.

#### Reagents

PRAME and *EZH2* short hairpin RNA vectors were kind gifts of Dr R Bernards (Amsterdam, The Netherlands) and were generated as previously described (Epping *et al.*, 2005). Antibodies against *EZH2* (4905) and phospho-FOXO3a (9465) were from Cell Signaling, Danvers, MA, USA. Anti-PRAME was from Abcam (ab32185) (Cambridge, MA, USA)

and anti-ACTIN was from ICN Biomedicals Inc. (C4) (Aurora, OH, USA). TRAIL R2-Fc and isoleucine-zipper-TRAIL recombinant proteins were generously provided by Dr Henning Walczak (Imperial College, London, UK).

#### Cell culture and cell lines

All cells were cultured in RPMI medium 1640 supplemented with 10% fetal bovine serum, 25 mM Hepes, 2 mM L-glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin, except for Phoenix packaging cell, which was grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum, 25 mM Hepes, 2 mM L-glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin and the KBM7 cell line, which was grown in Iscove's modified Dulbecco's medium supplemented with 20% fetal bovine serum, 25 mM Hepes, 2 mM L-glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin. HL-60 and K562 cells were obtained from

ATCC, Manassas, VA, USA. LAMA-84 was kindly provided by James Griffin (Dana-Farber Cancer Institute, Boston, MA, USA). HL-60.Bcr-Abl cells were derived from wild-type HL-60 by retroviral transfection with pSR $\alpha$ MSVp185<sup>bcr-abl</sup>tkneo (Amarante-Mendes *et al.*, 1998; Bueno-da-Silva *et al.*, 2003). SKW6.4 cells were kindly provided by Dr Henning Walczak (Imperial College). Phoenix packaging cells (kindly provided by Dr Gary Nolan, Stanford University, CA, USA) were transfected with retroviral plasmids to generate amphotropic retroviruses. K562 cells were infected with pRS (empty vector) or pRS-PRAME or pRS-EZH2 #3 or pRS-EZH2 #4 retrovirus and selected for puromycin resistance.

#### Western blot

Protein samples were resolved under reducing conditions as previously described (Souza-Fagundes *et al.*, 2003). Separated proteins were transferred onto polyvinylidene difluoride membranes and reactions were detected with a suitable secondary antibody conjugated to horseradish peroxidase (Jackson Laboratory, Bar Harbor, ME, USA and Amersham, Arlington, IL, USA) using enhanced chemiluminescence (Pierce, Rockford, IL, USA).

#### ChIP assay

Chromatin from the K562 cell lines was fractionated by incubation of purified nuclei with micrococcal nuclease (MNase) (Umlauf *et al.*, 2004). Chromatin immunoprecipitation with EZH2 antibody was performed as previously described (Umlauf *et al.*, 2004) and DNA extractions from bound fractions were performed following the Abcam (www.abcam.com) protocol. The immunoprecipitated DNA was analyzed by quantitative PCR. For a negative control we performed chromatin immunoprecipitation assay using only PTN A.

#### Quantitative PCR

Total RNA was extracted using Trizol (Invitrogen, Carlsbad, CA, USA). RNA concentration and purity were determined spectrophotometrically by measuring fluorescence at 260 and 280 nm. Three micrograms of RNA was reverse transcribed into cDNA using Superscript III (Invitrogen) transcription reagents according to the manufacturer's instructions. After obtaining the cDNA, gene expression was quantified by quantitative PCR using Platinum SYBRGreen Kit (Invitrogen) in Mx3005P detector equipment (Stratagene, Santa Clara, CA, USA).

The following primers were used: *BCR-ABL* 5'-GGGGTC CAGCGAGAAGGTT-3' (forward) and 5'-GCATCCGCTG ACCATCAAT-3' (reverse); *GAPDH* 5'-GGAGAAGGCTGG GGCTCAT-3' (forward) and 5'-GTCCTTCCACGATAC CAAAGTT-3' (reverse); *TRAIL* 5'-AAGGCTCTGGGCCGC AAAATAAAC-3' (forward) and 5'-GCCAACTAAAAAG GCCCGAAAAA-3' (reverse); *EZH2* 5'-AGGACGGCTCC TCTAACCAT-3' (forward) and 5'-CTTGGTGTTGCACT GTGCTT-3' (reverse). Results were given as relative expression in terms of the amplicon ratio: investigated gene/*gapdh* housekeeping gene. The PRAME quantitative PCR was

performed using TaqMan PCR master mix as previously described (Proto-Siqueira *et al.*, 2006).

The following primers were used for TRAIL promoter. Region 1: 5'-TCCAGCCTAACACACAGGCA-3' (forward) and 5'-GCAAACCTTCAGACACAAATTCTAATC-3' (reverse); region 2: 5'-GGACAGACCTGCGTGCTGA-3' (forward) and 5'-ACACGTAAGTTACAGCCACACAGAG-3' (reverse).

#### Assessment of apoptosis

Apoptosis was quantified using a fluorescence-activated cell sorter (FACS) caliber flow cytometer (Becton-Dickinson, Franklin Lakes, NJ, USA), by flow-cytometric analysis of DNA content as described earlier (Amarante-Mendes *et al.*, 1997). The results represent the average  $\pm$  s.d. in triplicate samples. Every experiment was repeated at least three times. The samples were also analyzed by Trypan blue exclusion to assess cell viability.

#### Meta-analysis

Patient information and gene expression data were obtained from and analyzed using OncoPrint. The microarray meta-analysis algorithms and statistical analysis used were as previously described (Rhodes *et al.*, 2004). *P*-values were calculated as described at <http://www.oncoPrint.org>, using adjustment for multiple testing and false discovery (Rhodes *et al.*, 2004).

#### Statistical analysis

Experiments were performed always in triplicate and at least three times. Kruskal-Wallis followed by Dunn's multiple comparison tests were used to compare gene expression data between controls and CML patients in different phases of the disease. Associations between *BCR-ABL* and *PRAME* or between *PRAME* and *TRAIL* mRNA levels were assessed through non-parametric Spearman's rank correlation test. One-way ANOVA and Tukey's post-test were used to compare gene expression data from knockdown cell lines. Differences between experimental groups were considered significant when *P* < 0.05. All statistical analysis was performed using GraphPad Prism version 5.00 for Windows (GraphPad Software, San Diego, CA, USA).

#### Conflict of interest

The authors declare no conflict of interest.

#### Acknowledgements

DDC, JMGL, WOP and AEBBS were recipients of fellowships from the Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP—Brazil). This work was supported by grants from FAPESP and from the Brazilian Research Council (CNPq—Brazil). We thank Drs Phillipa Taberlay, Jueng Soo You and Theresa Kelly for their critical review of the paper.

#### References

Altucci L, Rossin A, Raffelsberger W, Reitmair A, Chomienne C, Gronemeyer H. (2001). Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL. *Nat Med* 7: 680–686.

Amarante-Mendes GP, Jascur T, Nishioka WK, Mustelin T, Green DR. (1997). Bcr—Abl-mediated resistance to apoptosis is independent of PI 3-kinase activity. *Cell Death Differ* 4: 548–554.

- Amarante-Mendes GP, Naekyung Kim C, Liu L, Huang Y, Perkins CL, Green DR *et al.* (1998). Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3. *Blood* **91**: 1700–1705.
- Bedi A, Zehnbauser BA, Barber JP, Sharkis SJ, Jones RJ. (1994). Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. *Blood* **83**: 2038–2044.
- Beer DG, Kardia SL, Huang CC, Giordano TJ, Levin AM, Misek DE *et al.* (2002). Gene-expression profiles predict survival of patients with lung adenocarcinoma. *Nat Med* **8**: 816–824.
- Brumatti G, Weinlich R, Chehab CF, Yon M, Amarante-Mendes GP. (2003). Comparison of the anti-apoptotic effects of Bcr-Abl, Bcl-2 and Bcl-x(L) following diverse apoptogenic stimuli. *FEBS Lett* **541**: 57–63.
- Bueno-da-Silva AE, Brumatti G, Russo FO, Green DR, Amarante-Mendes GP. (2003). Bcr-Abl-mediated resistance to apoptosis is independent of constant tyrosine-kinase activity. *Cell Death Differ* **10**: 592–598.
- Clarke N, Jimenez-Lara AM, Voltz E, Gronemeyer H. (2004). Tumor suppressor IRF-1 mediates retinoid and interferon anticancer signaling to death ligand TRAIL. *EMBO J* **23**: 3051–3060.
- Cretney E, Takeda K, Yagita H, Glaccum M, Peschon JJ, Smyth MJ. (2002). Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. *J Immunol* **168**: 1356–1361.
- Daniels RA, Turley H, Kimberley FC, Liu XS, Mongkolsapaya J, Ch'En P *et al.* (2005). Expression of TRAIL and TRAIL receptors in normal and malignant tissues. *Cell Res* **15**: 430–438.
- Epping MT, Bernards R. (2006). A causal role for the human tumor antigen preferentially expressed antigen of melanoma in cancer. *Cancer Res* **66**: 10639–10642.
- Epping MT, Wang L, Edell MJ, Carlee L, Hernandez M, Bernards R. (2005). The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. *Cell* **122**: 835–847.
- Epping MT, Wang L, Plumb JA, Lieb M, Gronemeyer H, Brown R *et al.* (2007). A functional genetic screen identifies retinoic acid signaling as a target of histone deacetylase inhibitors. *Proc Natl Acad Sci USA* **104**: 17777–17782.
- Haqq C, Nosrati M, Sudilovsky D, Crothers J, Khodabakhsh D, Pulliam BL *et al.* (2005). The gene expression signatures of melanoma progression. *Proc Natl Acad Sci USA* **102**: 6092–6097.
- Hoek KS, Schlegel NC, Brafford P, Sucker A, Ugurel S, Kumar R *et al.* (2006). Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. *Pigment Cell Res* **19**: 290–302.
- Ikeda H, Lethe B, Lehmann F, van Baren N, Baurain JF, de Smet C *et al.* (1997). Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. *Immunity* **6**: 199–208.
- Insinga A, Monestiroli S, Ronzoni S, Gelmetti V, Marchesi F, Viale A *et al.* (2005). Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. *Nat Med* **11**: 71–76.
- Kikuchi S, Nagai T, Kunitama M, Kirito K, Ozawa K, Komatsu N. (2007). Active FKHRL1 overcomes imatinib resistance in chronic myelogenous leukemia-derived cell lines via the production of tumor necrosis factor-related apoptosis-inducing ligand. *Cancer Sci* **98**: 1949–1958.
- Kurzrock R, Gutterman JU, Talpaz M. (1988). The molecular genetics of Philadelphia chromosome-positive leukemias. *N Engl J Med* **319**: 990–998.
- McGahan AJ, Brown DG, Martin SJ, Amarante-Mendes GP, Cotter TG, Cohen GM *et al.* (1997). Downregulation of Bcr-Abl in K562 cells restores susceptibility to apoptosis: characterization of the apoptotic death. *Cell Death Differ* **4**: 95–104.
- Melo JV, Barnes DJ. (2007). Chronic myeloid leukaemia as a model of disease evolution in human cancer. *Nat Rev Cancer* **7**: 441–453.
- Nebbio A, Clarke N, Voltz E, Germain E, Ambrosino C, Bontempo P *et al.* (2005). Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. *Nat Med* **11**: 77–84.
- Nimmanapalli R, Porosnicu M, Nguyen D, Worthington E, O'Bryan E, Perkins C *et al.* (2001). Cotreatment with STI-571 enhances tumor necrosis factor alpha-related apoptosis-inducing ligand (TRAIL or apo-2L)-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. *Clin Cancer Res* **7**: 350–357.
- Oberthuer A, Hero B, Spitz R, Berthold F, Fischer M. (2004). The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome. *Clin Cancer Res* **10**: 4307–4313.
- Popnikolov NK, Gatalica Z, Adegboyega PA, Norris BA, Pasricha PJ. (2006). Downregulation of TNF-related apoptosis-inducing ligand (TRAIL)/Apo2L in Barrett's esophagus with dysplasia and adenocarcinoma. *Appl Immunohistochem Mol Morphol* **14**: 161–165.
- Proto-Siqueira R, Figueiredo-Pontes LL, Panepucci RA, Garcia AB, Rizzatti EG, Nascimento FM *et al.* (2006). PRAME is a membrane and cytoplasmic protein aberrantly expressed in chronic lymphocytic leukemia and mantle cell lymphoma. *Leuk Res* **30**: 1333–1339.
- Radich JP, Dai H, Mao M, Oehler V, Schelter J, Druker B *et al.* (2006). Gene expression changes associated with progression and response in chronic myeloid leukemia. *Proc Natl Acad Sci USA* **103**: 2794–2799.
- Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D *et al.* (2004). ONCOMINE: a cancer microarray database and integrated data-mining platform. *Neoplasia* **6**: 1–6.
- Richardson AL, Wang ZC, De Nicolo A, Lu X, Brown M, Miron A *et al.* (2006). X chromosomal abnormalities in basal-like human breast cancer. *Cancer Cell* **9**: 121–132.
- Sawyers CL. (1997). Signal transduction pathways involved in BCR-ABL transformation. *Baillieres Clin Haematol* **10**: 223–231.
- Sawyers CL. (1999). Chronic myeloid leukemia. *N Engl J Med* **340**: 1330–1340.
- Schmaltz C, Alpdogan O, Kappel BJ, Muriglan SJ, Rotolo JA, Ongchin J *et al.* (2002). T cells require TRAIL for optimal graft-versus-tumor activity. *Nat Med* **8**: 1433–1437.
- Sedger LM, Glaccum MB, Schuh JC, Kanaly ST, Williamson E, Kayagaki N *et al.* (2002). Characterization of the *in vivo* function of TNF-alpha-related apoptosis-inducing ligand, TRAIL/Apo2L, using TRAIL/Apo2L gene-deficient mice. *Eur J Immunol* **32**: 2246–2254.
- Souza-Fagundes EM, Brumatti G, Martins-Filho OA, Correa-Oliveira R, Zani CL, Amarante-Mendes GP. (2003). Myriadenolide, a labdane diterpene isolated from *Alomia myriadenia* (asteraceae) induces depolarization of mitochondrial membranes and apoptosis associated with activation of caspases-8, -9, and -3 in Jurkat and THP-1 cells. *Exp Cell Res* **290**: 420–426.
- Stearman RS, Dwyer-Nield L, Zerbe L, Blaine SA, Chan Z, Bunn Jr PA *et al.* (2005). Analysis of orthologous gene expression between human pulmonary adenocarcinoma and a carcinogen-induced murine model. *Am J Pathol* **167**: 1763–1775.
- Steinbach D, Pfaffendorf N, Wittig S, Gruhn B. (2007). PRAME expression is not associated with down-regulation of retinoic acid signaling in primary acute myeloid leukemia. *Cancer Genet Cytogenet* **177**: 51–54.
- Tajeddine N, Louis M, Vermylen C, Gala JL, Tombal B, Gailly P. (2008). Tumor associated antigen PRAME is a marker of favorable prognosis in childhood acute myeloid leukemia patients and modifies the expression of S100A4, Hsp 27, p21, IL-8 and IGFBP-2 *in vitro* and *in vivo*. *Leuk Lymphoma* **49**: 1123–1131.
- Takeda K, Smyth MJ, Cretney E, Hayakawa Y, Kayagaki N, Yagita H *et al.* (2002). Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. *J Exp Med* **195**: 161–169.
- Takeda K, Smyth MJ, Cretney E, Hayakawa Y, Yamaguchi N, Yagita H *et al.* (2001). Involvement of tumor necrosis factor-related apoptosis-inducing ligand in NK cell-mediated and IFN-

- gamma-dependent suppression of subcutaneous tumor growth. *Cell Immunol* **214**: 194–200.
- Takeda K, Yamaguchi N, Akiba H, Kojima Y, Hayakawa Y, Tanner JE *et al.* (2004). Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. *J Exp Med* **199**: 437–448.
- Umlauf D, Goto Y, Feil R. (2004). Site-specific analysis of histone methylation and acetylation. *Methods Mol Biol* **287**: 99–120.
- Uno K, Inukai T, Kayagaki N, Goi K, Sato H, Nemoto A *et al.* (2003). TNF-related apoptosis-inducing ligand (TRAIL) frequently induces apoptosis in Philadelphia chromosome-positive leukemia cells. *Blood* **101**: 3658–3667.
- van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M *et al.* (2002). Gene expression profiling predicts clinical outcome of breast cancer. *Nature* **415**: 530–536.
- Vigneswaran N, Baucum DC, Wu J, Lou Y, Bouquot J, Muller S *et al.* (2007). Repression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but not its receptors during oral cancer progression. *BMC Cancer* **7**: 108.
- Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M *et al.* (1999). Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand *in vivo*. *Nat Med* **5**: 157–163.
- Wang S, El-Deiry WS. (2003). TRAIL and apoptosis induction by TNF-family death receptors. *Oncogene* **22**: 8628–8633.
- Watari K, Tojo A, Nagamura-Inoue T, Nagamura F, Takeshita A, Fukushima T *et al.* (2000). Identification of a melanoma antigen, PRAME, as a BCR/ABL-inducible gene. *FEBS Lett* **466**: 367–371.
- Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK *et al.* (1995). Identification and characterization of a new member of the TNF family that induces apoptosis. *Immunity* **3**: 673–682.
- Yong AS, Keyvanfar K, Eniafe R, Savani BN, Rezvani K, Sloand EM *et al.* (2008). Hematopoietic stem cells and progenitors of chronic myeloid leukemia express leukemia-associated antigens: implications for the graft-versus-leukemia effect and peptide vaccine-based immunotherapy. *Leukemia* **22**: 1721–1727.

Supplementary Information accompanies the paper on the Oncogene website (<http://www.nature.com/onc>)